Zachary Roberts - 20 Jan 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
EVP of R&D
Signature
Veer Bhavnagri as attorney-in-fact
Issuer symbol
ALLO
Transactions as of
20 Jan 2023
Net transactions value
$0
Form type
4
Filing time
24 Jan 2023, 16:02:59 UTC
Previous filing
09 Jan 2023
Next filing
24 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +251,908 $0.000000 251,908 20 Jan 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +873,015 $0.000000 873,015 20 Jan 2023 Common Stock 873,015 $6.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on January 03, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.